Table 2.
Examples of FEx/DOC-derived bioactive molecules.
| Reference | Library Size | Biological Endpoint | Example Hit Structure | Potency |
|---|---|---|---|---|
| Bioactive Molecules Identified from Agnostic Compound Libraries | ||||
| Wolan and Sharpless 201963 | 132 | hNE (biochemical) |
|
IC50 = 0.24 μM |
| Moses and Sharpless 2022183 | 88 | hNE (biochemical) |
|
IC50 = 2.1 μM |
| Rakesh and Qin 2019186 | 82 | Staphylococcus aureus (bacterial) |
|
MIC 0.81 μg/mL |
| Dong, Zhang and Sharpless 2021187 | 41 | Staphylococcus aureus 43300 (bacterial) |
|
MIC 1.1 μg/mL |
| Moses 202018 | 151 | Staphylococcus aureus USA300 (bacterial) |
|
MIC 0.625 μg/mL |
| Murthy 2019188 | 24 | kanamycin-resistant Escherichia coli, MRSA (bacterial) |
|
MIC99 0.66 μg/mL (E. coli) 5.28 μg/mL (MRSA) |
| Xu and Zhao 2024189 | 32 | Rhizoctonia solani (fungi) |
|
EC50 = 1.5 μg/mL |
| Wu 201985 | 40a | HT-29 cell (cellular) |
|
EC50 = 70 nM |
| Bioactive Molecules from FEx-enabled High-throughput Medicinal Chemistry (HTMC) | ||||
| Sharpless and Wolan 202062 | 460a | SpeB (biochemical) |
|
Kd = 18 nM |
| Erb 2021190 | 576 (biochemical)a then 43 (cellular)a | ENL-YEATS |
|
EC50 = 63 nM (cellular) |
| Wilson and Wolan 202471 | 1,200a,b | Influenza H1 (cellular) |
|
EC50 = 0.7-19 nM (H1strains) |
| Erb 202488 | 3,180a | CRBN/GSPT1 (cellular) |
|
EC50 = 55 nM |
| Moses 202472 | 288c | PDAC organoid proliferation (hM1A line) |
|
IC50 = 6.8 nM |
| Liu, Qin and Tang 202346 | 102a | AChE (biochemical) |
|
IC50 = 94 nM |
Unpurified reaction mixtures used for screening.
Total number including amide coupling products.
Used after removal of solvent and byproduct.
SpeB = streptococcal pyrogenic exotoxin B. ENL = eleven-nineteen leukemia. YEATS = Yaf9, ENL, AF9, Taf14, and Sas5. CRBN = cereblon. GSPT1 = G1 to S phase transition 1. PDAC = pancreatic ductal adenocarcinoma. AChE = acetylcholinesterase. IC50 = half maximal inhibitory concentration. MIC = minimum inhibitory concentration. EC50 = half maximal effective concentration. Kd = dissociation constant.